Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17087480 | 0.86 | PAOX (0.37) | L3MBTL1 | |
| SCHEMBL17518388 | 0.84 | L3MBTL1 (0.46) | L3MBTL1 | |
| SCHEMBL17518309 | 0.83 | L3MBTL1 (0.49) | L3MBTL1 | |
| SCHEMBL17524667 | 0.81 | SIGMAR1 (0.40) | L3MBTL1 | |
| SCHEMBL17087400 | 0.81 | KDM4E (0.46) | — | |
| SCHEMBL17518363 | 0.81 | DPP4 (0.33) | L3MBTL1 | |
| SCHEMBL17087557 | 0.79 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL15810282 | 0.79 | RAB9A (0.36) | RAB9AL3MBTL1 | |
| SCHEMBL17518369 | 0.79 | POLB (0.31) | L3MBTL1 | |
| SCHEMBL17087405 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170007664-A1 | CYCLIC DEPSIPEPTIDE COMPOUNDS AND THEIR USES | CYPRALIS LIMITED (GB) | 2017-01-12 | — | — | US | disclosed |
| US-9382295-B2 | Cyclic depsipeptide compounds and their uses | CYPRALIS LIMITED (GB) | 2016-07-05 | — | — | US | disclosed |
| US-9266927-B2 | Cyclosporin A analogs | ALLERGAN, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20160039880-A1 | CYCLOSPORIN A ANALOGS | ALLERGAN, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20150259386-A1 | CYCLIC DEPSIPEPTIDE COMPOUNDS AND THEIR USES | CYPRALIS LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039880-A1 | CYCLOSPORIN A ANALOGS | TSLP, CHP1, PPP3R1 | RAB9A 2519/4885L3MBTL1 4873/4885 |
| US-20170007664-A1 | CYCLIC DEPSIPEPTIDE COMPOUNDS AND THEIR USES | FKBP14, FKBP1A, PIN1 | RAB9A 3026/4885L3MBTL1 3872/4885 |
| US-20150259386-A1 | CYCLIC DEPSIPEPTIDE COMPOUNDS AND THEIR USES | FKBP14, FKBP1A, PIN1 | RAB9A 3026/4885L3MBTL1 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.